Trending
Written by: Youssef Sebban | Eckuity Capital
For decades, healthcare investing has meant patience. Drug development could take a decade or more, medical devices often required years of validation, and reimbursement approvals moved at a glacial pace. Even the most promising innovations left investors waiting years for liquidity.
That’s starting to change. Private equity is reshaping how capital flows through healthcare - unlocking earlier returns and turning one of the world’s slowest-moving sectors into a more dynamic, investable asset class.
The driving forces behind this shift are twofold: the rapid rise of artificial intelligence (AI) as a productivity engine across healthcare, and private equity’s growing focus on commercial-stage companies that already have proven products, revenues, and regulatory clearance. Together, they are transforming how - and how quickly - value is realised.
AI Is Collapsing Timelines
Artificial intelligence is shortening the distance between research and revenue. Algorithms can now identify viable drug candidates in months instead of years, improve diagnostic accuracy through imaging and pattern recognition, and even predict patient outcomes before clinical symptoms appear.
The result is that innovations reach commercial readiness faster, reducing both technical risk and capital intensity. For investors, this means earlier proof points, shorter holding periods, and more opportunities to return capital without waiting for a full acquisition or IPO.
Liquidity as the New Benchmark
For many Limited Partners, the most important metric today isn’t paper gains - it’s DPI, or “Distributed to Paid-In Capital,” which measures how much cash has actually been returned. Healthcare private equity has traditionally lagged other sectors here, given its long development cycles. But new structures are changing that dynamic.
Leading firms are introducing continuation vehicles and NAV-based credit facilities that let them return capital to investors sooner while retaining exposure to high-performing assets. Strategic partnerships with large pharma groups, insurers, and hospital systems are also helping portfolio companies monetise earlier - through licensing, milestone payments, or partial exits.
At Eckuity Capital, we take this a step further through our commercialisation entities, which act as dedicated distribution platforms for each fund. These entities help portfolio companies scale faster, access strategic partners, and generate tangible revenue streams - with net proceeds flowing back to our investors as management fee offsets. It’s a structure designed to make DPI not just a measure of performance, but a philosophy of alignment.
The Next Phase of Healthcare Investing
Healthcare remains a $10 trillion global market, expanding faster than GDP and still rich with inefficiencies. But the liquidity profile of the sector is evolving. What used to be a long, binary journey - succeed or fail after 10 years - is becoming a series of shorter, measurable value inflection points.
Private equity’s playbook is evolving from patient capital to precision capital: targeted, data-driven, and designed for both impact and liquidity. Firms that combine deep domain expertise with disciplined, operational value creation will lead this next wave.
For investors, that means healthcare no longer has to be the “illiquid exception” in their portfolios. With AI as the catalyst and private equity as the engine, liquidity is coming to healthcare - and those who master it will define the next era of value creation.
Related: The $2.4 Trillion Blind Spot: Why Investors Still Miss the Opportunity in Women’s Health